Kunal S. Taskar
R&d
Stevenage, ENG, United Kingdom
Stevenage, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
Drug-drug interaction assessments of clinical transporter inhibition: Learnings from the Transporter Working Group of the International Consortium for Innovation and Quality in Pharmaceutical Development.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: November 14, 2025
PBPK Modelling of PROTACs: Learnings from ARV-110 as a Case Example.
Journal: The AAPS journal
Published: October 08, 2025
Physiologically-Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib.
Journal: CPT: pharmacometrics & systems pharmacology
Published: August 05, 2025
Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug-Drug Interaction Predictions.
Journal: Clinical pharmacology and therapeutics
Published: July 27, 2025
PBPK Modelling of Antisense Oligonucleotide Therapeutics: Application for Predicting Plasma and Tissue Pharmacokinetics of Bepirovirsen.
Journal: The AAPS journal
Published: July 08, 2025
Assessment of brain penetration and tumor accumulation of niraparib and olaparib: insights from multimodal imaging in preclinical models.
Journal: Scientific reports
Published: June 10, 2025
Physiologically-Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges.
Journal: CPT: pharmacometrics & systems pharmacology
Published: May 30, 2025
Physiologically Based Pharmacokinetic Modeling of Phosphate Prodrugs─Case Studies: Fostemsavir and Fostamatinib.
Journal: Molecular pharmaceutics
Published: March 26, 2025
Matrix Approach Assessment of Cabotegravir Drug-Drug Interactions with OAT1/OAT3 Substrates and UGT1A1/UGT1A9 Inhibitors Using Physiologically-Based Pharmacokinetic Modeling.
Journal: Pharmaceutics
Published: March 13, 2025
Bridging in vitro and clinical data: Experimental insights into the IC50 variability of dolutegravir as an organic cation transporter 2 inhibitor.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: January 09, 2025
Effects of Cimetidine and Dolutegravir on the Endogenous Drug-Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers.
Journal: Clinical pharmacology and therapeutics
Published: June 27, 2024
Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective.
Journal: Clinical pharmacology and therapeutics
Published: June 25, 2024
Last Updated: 09/26/2026